Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial

Fig. 1

Summary of joint involvement in patients with uncontrolled gout treated with pegloticase (biweekly 8 mg infusion) plus oral methotrexate (15 mg/week) for up to 52 weeks (light blue bar; 52 weeks [26 infusions] in 8 patients, 24 weeks [12 infusions] in 2 patients). Data represent mean values and error bars represent standard error. Weeks 64 and 76 represent the 3- and 6-month post-treatment follow-up visits, respectively. BL, baseline (last measurement prior to the first pegloticase infusion). Reproduced from Annals of the Rheumatic Diseases 80 (Suppl 1) 2021 with permission from BMJ Publishing Group Ltd

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us